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ABSTRACT
Objective: The quantification of drug and stability of nanoparticulate delivery systems is one of the major apprehensions in biomedical applications. 
The present research work was attempted to quantify phytic acid by utilizing ultraviolet (UV) spectroscopy method and to evaluate the stability of 
nanovesicular (niosomes) system containing phytic acid.
Methods: Niosomes containing phytic acid were developed by thin-film hydration method. Nanoformulation was subjected to stability testing as per 
the International Council for Harmonisation (ICH) guidelines. The formulation was stored at 30°C±2°C and 65%±5% RH, samples were withdrawn at 
15th, 30th, 60th, 90th, 120th, and 180th day of analysis and examined for the integrity of vesicular/particle size, polydispersity index, zeta potential, and 
percent encapsulation efficiency.
Results: Prepared nanoformulation displayed a straight line (y=mx+c) equation of y=−0.0309x+1.0413. Optimized batch of niosomes, which was 
prepared including dicetylphosphate showed zeta potential value of −36±0.36. Stability study showed that prepared niosomal formulation was stable 
up to 180 days at room temperature.
Conclusion: Findings of the current research work suggested that UV spectroscopy method can be effectively used for the quantification of phytic acid 
and niosomal formulation of phytic acid. The formulation was found to be stable as per the ICH guidelines for stability testing.
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INTRODUCTION
Phytic acid is a natural constituent present in almost all the cereals 
and legumes. It is extensively being studied to assess its effects 
on health and is shown to have chelation ability with minerals. It 
possesses various benefits on the human body such as lowering serum 
cholesterol, inhibitor for renal stone development, strong antioxidant, 
and antiangiogenic properties. It is confirmed by numerous researches 
that antioxidant scavenge free radicals, thus ultimately help in the 
cancer prevention. So far, molecular mechanism of action of phytic acid 
for chemoprevention is not very clear [1-3]. Previous in vitro and in vivo 
reports proved its anticancerous properties against prostate, colon, 
lung, metastatic, and mammary cancers [4].
Investigation and quantification are important elements in the 
formulation development of any drug. An appropriate method must 
exist for the quantification of the drug molecule in formulation for 
analysis of entrapment efficiency, dissolution studies, biological 
samples, etc. [5]. Ultraviolet (UV) spectroscopy is simplest and 
commonly used technique for such study. However, the UV region lies 
from 200 to 400 nm and visible region ranges from 400 to 800 nm. 
Phytic acid does not come under the UV region. Here comes the play 
of colorimetric analysis. Thus, phytic acid needs chromophores to be 
added for its quantification through UV spectroscopy.
Nanotechnology is meant for the development of nanomedicines 
that deliver drugs in a sustained or controlled mode and enhances 
residence time of drug [6]. Nanomedicine emerged as a new epoch with 
growth in the application of nanotechnology in the field of diagnosis 
and therapy. Nanoparticles are widely being used as pharmaceutical 
nanocarriers, and these include metallic, polymeric, vesicular, and 
lipidic nanoparticles [7,8]. Non-ionic surfactant vesicles (niosomes) 
are of intervening importance as a delivery system [9,10]. Niosomes 
are flexible carrier which is pertinent for systemic as well as topical 
applications [10]. These may be uni- or multi-lamellar spheroids in 
structures [11,12]. Niosomes are formed through self-assembly of non-
ionic surfactant monomers which are proficient in entrapping a variety 
of drugs (both hydrophilic and lipophilic) [12,13]. They generally 
exhibit a longer storage time and may also act as targeting agents [7,14].
Drug delivery systems play a key role in therapy development. The 
extension of the pharmaceutical industry and dosage form development 
is well-recognized [15]. Development of pharmaceutical products for 
global use necessitates that the prepared dosage form must be stable for 
longer duration along with persistent pharmacological potential [16]. 
Nanotechnologies being actively involved in the area remain linked 
with the development of effectual and stable dosage form [17]. To 
test the stability of newly developed dosage form is performed to 
show the evidence how properties change with the influence of time, 
temperature, and humidity or how long product may be used, thus to 
establish shelf lives [18, 19].
Phytic acid has momentous prospective to act as an antiangiogenic 
agent. Instead of having a great potential, it is grossly underutilized due 
to a flaw of rapid absorption and excretion from the body as it forms 
insoluble chelates when it comes in contact with biological ions. It is 
thus required to develop some novel drug delivery systems of phytic 
acid that can reduce its flaw, thereby increasing its anticancer effect. For 
the development of a novel delivery system, it is required to quantify it 
effectively through proper method for precise characterization. Hence, 
the endeavor of the current work was to quantify phytic acid and 
develop and characterize a niosomal delivery system of it.
© 2018 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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METHODS
Materials
Phytic acid and ammonium iron (III) sulfate.12 H2O were purchased 
from Sigma Co. (St. Louis, MO). 2,2’-bipyridine was procured from 
Abcam. Thioglycolic acid was purchased from Merck-millipore. All 
other chemicals were obtained from local commercial source and were 
of analytical grade.
Quantitative estimation of drug through UV-spectrophotometer
Quantitative estimation of phytic acid was performed as reported by 
Haug and Lantzsch [20]. Drug stock solution (100 µg/ml) was prepared 
in distilled water, named as the solution (i). Ferric solution was prepared 
separately by dissolving 0.2 g ammonium iron (III) sulfate.12 H2O in 100 ml 
2 N HCl and volumes were made up to 1000 ml with distilled water, solution 
named as the solution (ii). Solution (iii) was prepared by dissolving 10 g 
2,2’-bipyridine and 10 ml thioglycolic acid in distilled water and volume 
make up to 1000 ml. 0.5 ml of drug solution was pipetted (3–30 µg/ml) 
into a test tube, 1 ml of solution (ii) added to it and covered with parafilm. 
Tubes were heated in a boiling water bath for 30 min, by taking care for 
the first 5 min that the tubes remain well covered. After that, tubes were 
cooled in ice water for 15 min and allowed to adjust to room temperature. 
Once the tubes had reached room temperature, the content of tubes was 
mixed and centrifuged for 30 min at 3000 g. 1 ml of the supernatant was 
transferred to another test tube and 1.5 ml of solution (iii) was added. 
Solutions were scanned from a range of 400–600 nm, and the observed 
absorbance maxima value was utilized for further evaluations.
Table 1: Composition of the different batches of formulation of 






1(NIO1) 1:1 1 0
2(NIO2) 1:2.5 1 0
3(NIO3) 1:1 2 0
4(NIO4) 1:2.5 2 0
5(NIO5) 1:1 1 5
6(NIO6) 1:2.5 1 5
7(NIO7) 1:1 2 5
8(NIO8) 1:2.5 2 5
9(NIO9) 1:1.25 0.5 2.5











Values are given as mean±SD and experiments were performed in triplicate for 
each batch, i.e., n=3. SD: Standard deviation
Table 3: Effect of storage on particle size, PDI, zeta potential, and percent encapsulation efficiency, where n=3
Interval in days Particle size (nm±SD) PDI (values±SD) Zeta potential (values±SD) Encapsulation efficiency (%±SD)
0 day 965.5±65.2 0.386±0.08 −36±0.28 82.9±2.6
15th day 966.3±71.2 0.312±0.02 −36±0.31 81.2±3.8
30th day 972.3±63.2 0.319±0.03 −35±0.42 81.3±3.6
60th day 979.0±76.3 0.421±0.08 −35±0.52 80.0±4.8
90th day 983.5±87.4 0.376±0.07 −34±0.35 78.3±2.8
120th day 988.0±75.7 0.436±0.07 −32±0.38 78.1±4.3
180th day 990.3±82.3 0.348±0.08 −32±0.56 76.0±3.6
Values have been reported as mean±SD, experiments were performed in triplicate for each parameter, i.e., n=3. SD: Standard deviation, PDI: Polydispersity index
Preparation of phytic acid containing niosomes
Niosomes were prepared through thin-film hydration method and 
dispersed in a suitable suspension base. Detailed preparation and 
characterization of the formulation are reported elsewhere [21,22]. 
Briefly, niosomes were prepared using Span 80-Chol-dicetylphosphate 
(DCP) dispersion. An appropriate quantity of cholesterol, surfactant, 
and stabilizing agent in variable molar ratios (Table 1) was dissolved 
in 10 ml of chloroform in a round-bottomed glass flask. The chloroform 
was allowed to evaporate at 45°C under reduced pressure using a 
rotary evaporator (IKA® Rotavapor, Bengaluru, India). After solvent 
evaporation, the flask was kept overnight to remove residual solvent, 
resulting in the formation of a thin film. The thin film was hydrated with 
5 ml of aqueous drug solution by rotating at 45°C and 120 revolutions 
per minute (rpm). This dispersion was sonicated at 80% energy for 
1 min by utilizing probe-type sonicator (Labsonic®-M, Sartorius stedim) 
and kept for 24 h at 4°C for maturation.
Zeta potential measurement
Zeta potential of the niosomal formulation was measured using 
Malvern Zetasizer Nano ZS. It was determined by the electrophoretic 
mobility of niosome suspension in U-type tube, temperature set during 
the procedure was 25°C. Zeta potential was determined through the 
principle of dynamic light scattering [23].
Stability study of phytic acid containing niosomes
Prepared formulation was examined for stability testing according 
to the International Council for Harmonisation guidelines. The 
rationale of stability testing is to substantiate how the properties and 
entrapped drug amount of formulation vary with time under the effect 
of temperature and humidity [24]. Optimization was done previously 
through various characterization parameters. The optimized batch 
of the niosomal suspension was used for stability testing. Stability 
study of the niosomal formulation was carried out by estimating the 
ability of the prepared system to retain the physical properties. The 
formulation was kept for analysis at room temperature condition, 
namely 30°C±2°C/60%±5% RH. Samples were withdrawn at 15th, 30th, 
60th, 90th, 120th, and 180th day and were examined for particle size, 
polydispersity index, zeta potential by Malvern Zetasizer Nano ZS, 
particle and zeta analyzer, and percent encapsulation efficiency through 
spectrophotometrically. Estimation procedure of these parameters 
reported elsewhere [22].
RESULTS AND DISCUSSION
Quantitative estimation of drug through UV-spectrophotometer
UV-spectrophotometric method was successfully used for the 
quantification of phytic acid. Processed phytic acid solutions were 
scanned from 400 to 600 nm, as shown in Fig. 1. Scanning showed 
absorbance maxima at 520 nm, result was found in accordance with 
the previous report [20]. Thus, all the absorbances were measured at 
520 nm against distilled water. A representative calibration curve was 
obtained which was found linear till the concentration of 30 µg/ ml. 
Suggested concentration range of analysis is 3–30 µg/ml. Straight line 
(y=mx+c) equation was found to be “y=−0.0309x+1.0413” (Fig. 2), 
which was utilized for all further characterizations. Negative value 
suggests lower the absorbance higher will be the concentration of drug 
present in the solution and vice versa.
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Fig. 1: Ultraviolet spectrum of phytic acid displaying it absorption 
maxima near 520 nm
Fig. 2: Standard curve of phytic acid utilizing ultraviolet method
Experiments were performed in triplicate, i.e., n=3.
Preparation and characterization of phytic acid containing 
niosomes
Niosomes were prepared using thin-film hydration method and were 
dispersed in a base which was suitable for topical application. Extensive 
characterization (in vitro and in vivo) of prepared niosomal formulations 
was performed which have been reported elsewhere [22]. Prepared 
niosomes, when analyzed through scanning electron microscope, were 
found to be spherical, as shown in Fig. 3, resembling characteristic of 
noisome vesicles [7].
Zeta potential measurement
Zeta potential values for prepared niosomes are presented in Table 2. 
Zeta potential is related to the magnitude of the electrical charge 
present at the particle surface, and it indicates the degree of repulsion 
between adjacent particles. Either negative or positive, high zeta 
potential confers stability by resisting aggregation [23]. Negative 
value of the particle may be due to the presence of negative charge 
inducing agent, DCP. Batches which did not contain DCP showed lower 
values and those which contained DCP displayed higher values of zeta 
potential. This observation was in-line with characteristic property 
of DCP, i.e., inducing charge on the surface of the prepared vesicles to 
impart stability [25,26].
Stability study of phytic acid containing niosomes
Optimized formulation was kept for stability testing at above-mentioned 
condition. Results of stability study showed that the prepared niosomal 
formulation was stable up to 180 days at room temperature (Table 3). 
All the parameters were found stable during the analysis. This may be 
attributed to the presence of DCP which has the property to induce 
charge on the surface of the vesicles and would not allow its aggregation, 
thereby enhancing its stability [25,26]. No significant degradation was 
observed on storage at the condition of 30°C±2°C/60%±5%. Thus, shelf 
life of prepared formulation is estimated to be high.
CONCLUSION
In the present study, the findings revealed that UV spectroscopy 
method can be efficiently utilized for the quantification of phytic 
acid. DCP may be utilized as a charge inducing and stabilizing agent 
for the preparation of niosomes. Niosomal formulation of phytic acid 
was successfully prepared using DCP and through thin-film hydration 
method. Thus, prepared system was stable up to 180 days, i.e., it can be 
stored at room temperature for sufficient period.
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